SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) hosted the Tumor Infiltrating Lymphocytes (TIL) Symposium during the 39^th Annual Meeting & Pre-Conference Programs on November 6, 2024. Available here are the presentation slides and video from Session I: The Path to TIL Approval and Current Clinical Management” as permitted by presenters.

Program Organizers

• Chantale Bernatchez, PhD – CTMC
• Stephanie Goff, MD, FACS  – National Cancer Institute
• Shari Pilon-Thomas, PhD – H. Lee Moffitt Cancer Center and Research Institute

Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.

Program Description

As part of the 39^th Annual Meeting & Pre-Conference Programs (SITC 2024), the SITC Tumor Infiltrating Lymphocytes (TIL) Symposium pre-conference program provides an opportunity for an in-depth discussion on a specific topic in the field of IO. This program will provide an overview of the path to approval for TIL therapy, current clinical management, and the impact of recent FDA-approved therapies while exploring next generation TIL and innovative pre-clinical development. Through didactic presentations and panels to engage an interdisciplinary audience, the program aims to bring the field together to educate and promote the continued utilization and development of TIL therapies to address hurdles in cancer immunotherapy. 

Learning Objectives

• Summarize current clinical management processes for TIL therapy and understand the regulatory history of current approved agents
• Characterize ongoing clinical studies of TIL therapy in new diseases and settings
• Discuss pre-clinical studies concerning development of novel TIL-focused strategies

To view the entire program schedule (including presenter permission to post) please click here.